Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11,12-epoxyeicosatrienoic acid (11,12-EET) is a bioactive lipid metabolite of arachidonic acid, synthesized primarily by cytochrome P450 (CYP) epoxygenases. It functions as an autocrine and paracrine signaling molecule with significant roles in cardiovascular and renal physiology. 11,12-EET is recognized as an endothelium-derived hyperpolarizing factor (EDHF) that promotes vasodilation by activating large-conductance calcium-activated potassium (BKCa) channels in vascular smooth muscle cells, leading to membrane hyperpolarization and relaxation. Beyond its vasodilatory effects, 11,12-EET exhibits anti-inflammatory, anti-apoptotic, and cardioprotective properties. OMM Scientific provides the racemic (±) form of 11,12-EET as a research reagent for preclinical investigation into its therapeutic potential for conditions such as hypertension, inflammation, and ischemic injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11,12-epoxyeicosatrienoic acid.